Repositório Covid-1918/11/2021 Retrospective Analysis of Clinical Laboratory Parameters, Therapeutics and Outcome in Patients Infected with SARS-CoV2SARS-CoV-2 is the third coronavirus to have caused severe disease in humans in the last two decades, with approximately 5%...16/11/2021 Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2COVID-19, for which no confirmed therapeutic agents are available, has claimed over 48,14,000 lives globally. A feasible and quicker method...16/11/2021 Two years into COVID-19 – Lessons in SARS-CoV-2 and a perspective from papers in FEBS LettersThe 2019 outbreak of coronavirus disease (COVID-19) in Wuhan (Hubei province of China) has given rise to a pandemic spread...15/11/2021 COMPARISON OF REMDESIVIR AND FAVIPIRAVIR - THE ANTI-COVID-19 AGENTS MIMICKING PURINE RNA CONSTITUENTSBy December 2019, humanity was challenged by a new infectious respiratory disease named coronavirus disease of 2019 or COVID-19. This...14/11/2021 The role of microRNAs in solving COVID-19 puzzle from infection to therapeutics: A mini-reviewNowadays, one of the major global health concerns is coronavirus disease 2019 (COVID-19), which is caused by the severe acute...11/11/2021 Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialWe report the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like...11/11/2021 Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trialConcomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of...09/11/2021 Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of AgeSafe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in children younger than 12 years of age.03/11/2021 Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trialChAdOx1-vectored vaccine candidates against several pathogens have been developed and tested in clinical trials and ChAdOx1 nCoV-19 has now been...03/11/2021 Corticosteroid treatment in COVID-19 modulates host inflammatory responses and transcriptional signatures of immune dysregulationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease-2019 (COVID-19), a respiratory disease that varies...03/11/2021 Dasabuvir Inhibits Human Norovirus Infection in Human Intestinal EnteroidsHuman noroviruses (HuNoVs) are acute viral gastroenteritis pathogens that affect all age groups, yet no approved vaccines and drugs to...03/11/2021 Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance dataIn the USA, COVID-19 vaccines became available in mid-December, 2020, with adults aged 65 years and older among the first...
18/11/2021 Retrospective Analysis of Clinical Laboratory Parameters, Therapeutics and Outcome in Patients Infected with SARS-CoV2SARS-CoV-2 is the third coronavirus to have caused severe disease in humans in the last two decades, with approximately 5%...
16/11/2021 Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2COVID-19, for which no confirmed therapeutic agents are available, has claimed over 48,14,000 lives globally. A feasible and quicker method...
16/11/2021 Two years into COVID-19 – Lessons in SARS-CoV-2 and a perspective from papers in FEBS LettersThe 2019 outbreak of coronavirus disease (COVID-19) in Wuhan (Hubei province of China) has given rise to a pandemic spread...
15/11/2021 COMPARISON OF REMDESIVIR AND FAVIPIRAVIR - THE ANTI-COVID-19 AGENTS MIMICKING PURINE RNA CONSTITUENTSBy December 2019, humanity was challenged by a new infectious respiratory disease named coronavirus disease of 2019 or COVID-19. This...
14/11/2021 The role of microRNAs in solving COVID-19 puzzle from infection to therapeutics: A mini-reviewNowadays, one of the major global health concerns is coronavirus disease 2019 (COVID-19), which is caused by the severe acute...
11/11/2021 Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialWe report the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like...
11/11/2021 Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trialConcomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of...
09/11/2021 Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of AgeSafe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in children younger than 12 years of age.
03/11/2021 Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trialChAdOx1-vectored vaccine candidates against several pathogens have been developed and tested in clinical trials and ChAdOx1 nCoV-19 has now been...
03/11/2021 Corticosteroid treatment in COVID-19 modulates host inflammatory responses and transcriptional signatures of immune dysregulationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease-2019 (COVID-19), a respiratory disease that varies...
03/11/2021 Dasabuvir Inhibits Human Norovirus Infection in Human Intestinal EnteroidsHuman noroviruses (HuNoVs) are acute viral gastroenteritis pathogens that affect all age groups, yet no approved vaccines and drugs to...
03/11/2021 Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance dataIn the USA, COVID-19 vaccines became available in mid-December, 2020, with adults aged 65 years and older among the first...